A gene therapy for hemophilia A has shown positive results after three years of follow up in a major late-stage clinical trial.
Developed by Californian genetics specialist BioMarin Pharmaceutical (Nasdaq: BMRN), Roctavian (valoctocogene roxaparvovec) is a one-time treatment for adults with severe hemophilia A.
Data from the ongoing GENEr8-1 study of the candidate show that the average bleed rate was reduced by 80% from baseline, while usage of Factor VIII was reduced by 94% in the third year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze